We believe the future of targeting AXL in AML involves a combinatorial approach with other targeted therapies, and our data further validate this idea and demonstrates the importance of combining AXL inhibition concurrently with FLT3 TKI to combat early adaptive resistance as well as later‐occurring acquired resistance. The gene discussed is AXL; the disease is acute myeloid leukemia.